A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer

G. Galffy; I. Lugowska; E. V. Poddubskaya; B. C. Cho; M. J. Ahn; J. Y. Han; W. C. Su; R. J. Hauke; S. H. Dyar; D. H. Lee; P. Serwatowski; D. L. Estelles; V. R. Holden; Y. J. Kim; V. Vladimirov; Z. Horvath; A. Ghose; A. Goldman; A. di Pietro; J. Wang; D. A. Murphy; A. Alhadab; M. Laskov

doi:10.1016/j.esmoop.2023.101173

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer

G. Galffy, I. Lugowska, E. V. Poddubskaya, B. C. Cho, M. J. Ahn, J. Y. Han, W. C. Su, R. J. Hauke, S. H. Dyar, D. H. Lee, P. Serwatowski, D. L. Estelles, V. R. Holden, Y. J. Kim, V. Vladimirov, Z. Horvath, A. Ghose, A. Goldman, A. di Pietro, J. WangD. A. Murphy, A. Alhadab, M. Laskov

Department of Oncology

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Background: We hypothesized that avelumab plus axitinib could improve clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC) or urothelial carcinoma (UC). Patients and methods: We enrolled previously treated patients with advanced or metastatic NSCLC, or untreated, cisplatin-ineligible patients with advanced or metastatic UC. Patients received avelumab 800 mg every 2 weeks (Q2W) and axitinib 5 mg orally two times daily. The primary endpoint was objective response rate (ORR). Immunohistochemistry was used to assess programmed death-ligand 1 (PD-L1) expression (SP263 assay) and the presence of CD8+ T cells (clone C8/144B). Tumor mutational burden (TMB) was assessed by whole-exome sequencing. Results: A total of 61 patients were enrolled and treated (NSCLC, n = 41; UC, n = 20); 5 remained on treatment at data cut-off (26 February 2021). The confirmed ORR was 31.7% in the NSCLC cohort and 10.0% in the UC cohort (all partial responses). Antitumor activity was observed irrespective of PD-L1 expression. In exploratory subgroups, ORRs were higher in patients with higher (≥median) CD8+ T cells in the tumor. ORRs were higher in patients with lower TMB (<median) in the NSCLC cohort and higher TMB (≥median) in the UC cohort. Treatment-related adverse events (TRAEs) occurred in 93.4% of patients, including grade ≥3 TRAEs in 55.7%. Avelumab exposures with 800 mg Q2W dosing were similar to those observed with 10 mg/kg Q2W dosing. Conclusions: In previously treated patients with advanced/metastatic NSCLC, ORR appeared to be superior to anti-PD-L1 or anti-programmed cell death protein 1 monotherapy, irrespective of PD-L1 status, whereas in untreated, cisplatin-ineligible patients with advanced/metastatic UC, ORR was lower than expected, potentially limited by small patient numbers. Trial registration: Clinicaltrial.gov NCT03472560; https://clinicaltrials.gov/ct2/show/NCT03472560

Original language	English
Article number	101173
Journal	ESMO Open
Volume	8
Issue number	3
DOIs	https://doi.org/10.1016/j.esmoop.2023.101173
Publication status	Published - 2023 Jun

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.esmoop.2023.101173

Cite this

Galffy, G., Lugowska, I., Poddubskaya, E. V., Cho, B. C., Ahn, M. J., Han, J. Y., Su, W. C., Hauke, R. J., Dyar, S. H., Lee, D. H., Serwatowski, P., Estelles, D. L., Holden, V. R., Kim, Y. J., Vladimirov, V., Horvath, Z., Ghose, A., Goldman, A., di Pietro, A., ... Laskov, M. (2023). A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer. ESMO Open, 8(3), Article 101173. https://doi.org/10.1016/j.esmoop.2023.101173

@article{c718cfdf3e6e4213bfc9b39a81f89c46,

title = "A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-na{\"i}ve, cisplatin-ineligible urothelial cancer",

abstract = "Background: We hypothesized that avelumab plus axitinib could improve clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC) or urothelial carcinoma (UC). Patients and methods: We enrolled previously treated patients with advanced or metastatic NSCLC, or untreated, cisplatin-ineligible patients with advanced or metastatic UC. Patients received avelumab 800 mg every 2 weeks (Q2W) and axitinib 5 mg orally two times daily. The primary endpoint was objective response rate (ORR). Immunohistochemistry was used to assess programmed death-ligand 1 (PD-L1) expression (SP263 assay) and the presence of CD8+ T cells (clone C8/144B). Tumor mutational burden (TMB) was assessed by whole-exome sequencing. Results: A total of 61 patients were enrolled and treated (NSCLC, n = 41; UC, n = 20); 5 remained on treatment at data cut-off (26 February 2021). The confirmed ORR was 31.7% in the NSCLC cohort and 10.0% in the UC cohort (all partial responses). Antitumor activity was observed irrespective of PD-L1 expression. In exploratory subgroups, ORRs were higher in patients with higher (≥median) CD8+ T cells in the tumor. ORRs were higher in patients with lower TMB (",

author = "G. Galffy and I. Lugowska and Poddubskaya, {E. V.} and Cho, {B. C.} and Ahn, {M. J.} and Han, {J. Y.} and Su, {W. C.} and Hauke, {R. J.} and Dyar, {S. H.} and Lee, {D. H.} and P. Serwatowski and Estelles, {D. L.} and Holden, {V. R.} and Kim, {Y. J.} and V. Vladimirov and Z. Horvath and A. Ghose and A. Goldman and {di Pietro}, A. and J. Wang and Murphy, {D. A.} and A. Alhadab and M. Laskov",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = jun,

doi = "10.1016/j.esmoop.2023.101173",

language = "English",

volume = "8",

journal = "ESMO Open",

issn = "2059-7029",

publisher = "BMJ Publishing Group",

number = "3",

}

Galffy, G, Lugowska, I, Poddubskaya, EV, Cho, BC, Ahn, MJ, Han, JY, Su, WC, Hauke, RJ, Dyar, SH, Lee, DH, Serwatowski, P, Estelles, DL, Holden, VR, Kim, YJ, Vladimirov, V, Horvath, Z, Ghose, A, Goldman, A, di Pietro, A, Wang, J, Murphy, DA, Alhadab, A & Laskov, M 2023, 'A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer', ESMO Open, vol. 8, no. 3, 101173. https://doi.org/10.1016/j.esmoop.2023.101173

TY - JOUR

T1 - A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer

AU - Galffy, G.

AU - Lugowska, I.

AU - Poddubskaya, E. V.

AU - Cho, B. C.

AU - Ahn, M. J.

AU - Han, J. Y.

AU - Su, W. C.

AU - Hauke, R. J.

AU - Dyar, S. H.

AU - Lee, D. H.

AU - Serwatowski, P.

AU - Estelles, D. L.

AU - Holden, V. R.

AU - Kim, Y. J.

AU - Vladimirov, V.

AU - Horvath, Z.

AU - Ghose, A.

AU - Goldman, A.

AU - di Pietro, A.

AU - Wang, J.

AU - Murphy, D. A.

AU - Alhadab, A.

AU - Laskov, M.

PY - 2023/6

Y1 - 2023/6

N2 - Background: We hypothesized that avelumab plus axitinib could improve clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC) or urothelial carcinoma (UC). Patients and methods: We enrolled previously treated patients with advanced or metastatic NSCLC, or untreated, cisplatin-ineligible patients with advanced or metastatic UC. Patients received avelumab 800 mg every 2 weeks (Q2W) and axitinib 5 mg orally two times daily. The primary endpoint was objective response rate (ORR). Immunohistochemistry was used to assess programmed death-ligand 1 (PD-L1) expression (SP263 assay) and the presence of CD8+ T cells (clone C8/144B). Tumor mutational burden (TMB) was assessed by whole-exome sequencing. Results: A total of 61 patients were enrolled and treated (NSCLC, n = 41; UC, n = 20); 5 remained on treatment at data cut-off (26 February 2021). The confirmed ORR was 31.7% in the NSCLC cohort and 10.0% in the UC cohort (all partial responses). Antitumor activity was observed irrespective of PD-L1 expression. In exploratory subgroups, ORRs were higher in patients with higher (≥median) CD8+ T cells in the tumor. ORRs were higher in patients with lower TMB (

AB - Background: We hypothesized that avelumab plus axitinib could improve clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC) or urothelial carcinoma (UC). Patients and methods: We enrolled previously treated patients with advanced or metastatic NSCLC, or untreated, cisplatin-ineligible patients with advanced or metastatic UC. Patients received avelumab 800 mg every 2 weeks (Q2W) and axitinib 5 mg orally two times daily. The primary endpoint was objective response rate (ORR). Immunohistochemistry was used to assess programmed death-ligand 1 (PD-L1) expression (SP263 assay) and the presence of CD8+ T cells (clone C8/144B). Tumor mutational burden (TMB) was assessed by whole-exome sequencing. Results: A total of 61 patients were enrolled and treated (NSCLC, n = 41; UC, n = 20); 5 remained on treatment at data cut-off (26 February 2021). The confirmed ORR was 31.7% in the NSCLC cohort and 10.0% in the UC cohort (all partial responses). Antitumor activity was observed irrespective of PD-L1 expression. In exploratory subgroups, ORRs were higher in patients with higher (≥median) CD8+ T cells in the tumor. ORRs were higher in patients with lower TMB (

UR - http://www.scopus.com/inward/record.url?scp=85154056694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85154056694&partnerID=8YFLogxK

U2 - 10.1016/j.esmoop.2023.101173

DO - 10.1016/j.esmoop.2023.101173

M3 - Article

C2 - 37141847

AN - SCOPUS:85154056694

SN - 2059-7029

VL - 8

JO - ESMO Open

JF - ESMO Open

IS - 3

M1 - 101173

ER -

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this